These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 24498557

  • 1. A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma.
    Chandramohan V, Bigner DD.
    Oncoimmunology; 2013 Dec 01; 2(12):e26852. PubMed ID: 24498557
    [Abstract] [Full Text] [Related]

  • 2. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.
    Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, Bigner DD.
    Clin Cancer Res; 2013 Sep 01; 19(17):4717-27. PubMed ID: 23857604
    [Abstract] [Full Text] [Related]

  • 3. EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery.
    Bao X, Pastan I, Bigner DD, Chandramohan V.
    Receptors Clin Investig; 2016 Sep 01; 3(4):. PubMed ID: 28286803
    [Abstract] [Full Text] [Related]

  • 4. Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial.
    Chandramohan V, Pegram CN, Piao H, Szafranski SE, Kuan CT, Pastan IH, Bigner DD.
    Appl Microbiol Biotechnol; 2017 Apr 01; 101(7):2747-2766. PubMed ID: 28013405
    [Abstract] [Full Text] [Related]

  • 5. Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.
    Chandramohan V, Bao X, Yu X, Parker S, McDowall C, Yu YR, Healy P, Desjardins A, Gunn MD, Gromeier M, Nair SK, Pastan IH, Bigner DD.
    J Immunother Cancer; 2019 May 29; 7(1):142. PubMed ID: 31142380
    [Abstract] [Full Text] [Related]

  • 6. Preclinical toxicity evaluation of a novel immunotoxin, D2C7-(scdsFv)-PE38KDEL, administered via intracerebral convection-enhanced delivery in rats.
    Bao X, Chandramohan V, Reynolds RP, Norton JN, Wetsel WC, Rodriguiz RM, Aryal DK, McLendon RE, Levin ED, Petry NA, Zalutsky MR, Burnett BK, Kuan CT, Pastan IH, Bigner DD.
    Invest New Drugs; 2016 Apr 29; 34(2):149-58. PubMed ID: 26728879
    [Abstract] [Full Text] [Related]

  • 7. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
    Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Otu H, Libermann TA, Raisanen JM, Ashfaq R, Wong ET, Wu J, Elliott R, Habib AA.
    Cancer Res; 2006 Jan 15; 66(2):867-74. PubMed ID: 16424019
    [Abstract] [Full Text] [Related]

  • 8. Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models.
    Parker S, McDowall C, Sanchez-Perez L, Osorio C, Duncker PC, Briley A, Swartz AM, Herndon JE, Yu YA, McLendon RE, Tedder TF, Desjardins A, Ashley DM, Gunn MD, Enterline DS, Knorr DA, Pastan IH, Nair SK, Bigner DD, Chandramohan V.
    Sci Transl Med; 2023 Feb 08; 15(682):eabn5649. PubMed ID: 36753564
    [Abstract] [Full Text] [Related]

  • 9. Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.
    Johnson H, Del Rosario AM, Bryson BD, Schroeder MA, Sarkaria JN, White FM.
    Mol Cell Proteomics; 2012 Dec 08; 11(12):1724-40. PubMed ID: 22964225
    [Abstract] [Full Text] [Related]

  • 10. EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines.
    Bax DA, Gaspar N, Little SE, Marshall L, Perryman L, Regairaz M, Viana-Pereira M, Vuononvirta R, Sharp SY, Reis-Filho JS, Stávale JN, Al-Sarraj S, Reis RM, Vassal G, Pearson AD, Hargrave D, Ellison DW, Workman P, Jones C.
    Clin Cancer Res; 2009 Sep 15; 15(18):5753-61. PubMed ID: 19737945
    [Abstract] [Full Text] [Related]

  • 11. Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors.
    Zalutsky MR, Boskovitz A, Kuan CT, Pegram CN, Ayriss J, Wikstrand CJ, Buckley AF, Lipp ES, Herndon JE, McLendon RE, Bigner DD.
    Nucl Med Biol; 2012 Jan 15; 39(1):23-34. PubMed ID: 21958852
    [Abstract] [Full Text] [Related]

  • 12. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
    Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, Oka K, Ishimaru Y, Ushio Y.
    Cancer Res; 2003 Oct 15; 63(20):6962-70. PubMed ID: 14583498
    [Abstract] [Full Text] [Related]

  • 13. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates.
    Wu G, Barth RF, Yang W, Kawabata S, Zhang L, Green-Church K.
    Mol Cancer Ther; 2006 Jan 15; 5(1):52-9. PubMed ID: 16432162
    [Abstract] [Full Text] [Related]

  • 14. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S, Crescenzi E, Colecchia D, Carpentieri A, Amoresano A, Fedele M, Chiariello M, Cerchia L.
    Oncotarget; 2015 Nov 10; 6(35):37570-87. PubMed ID: 26461476
    [Abstract] [Full Text] [Related]

  • 15. Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFRY1068 Phosphorylation.
    von Achenbach C, Silginer M, Blot V, Weiss WA, Weller M.
    Mol Cancer Ther; 2020 Jun 10; 19(6):1328-1339. PubMed ID: 32371586
    [Abstract] [Full Text] [Related]

  • 16. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas.
    Biernat W, Huang H, Yokoo H, Kleihues P, Ohgaki H.
    Brain Pathol; 2004 Apr 10; 14(2):131-6. PubMed ID: 15193025
    [Abstract] [Full Text] [Related]

  • 17. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
    Jiang H, Gao H, Kong J, Song B, Wang P, Shi B, Wang H, Li Z.
    Cancer Immunol Res; 2018 Nov 10; 6(11):1314-1326. PubMed ID: 30201736
    [Abstract] [Full Text] [Related]

  • 18. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.
    Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, Aldape K.
    Clin Cancer Res; 2005 Feb 15; 11(4):1462-6. PubMed ID: 15746047
    [Abstract] [Full Text] [Related]

  • 19. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.
    Chistiakov DA, Chekhonin IV, Chekhonin VP.
    Eur J Pharmacol; 2017 Sep 05; 810():70-82. PubMed ID: 28583430
    [Abstract] [Full Text] [Related]

  • 20. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
    Nitta Y, Shimizu S, Shishido-Hara Y, Suzuki K, Shiokawa Y, Nagane M.
    Cancer Med; 2016 Mar 05; 5(3):486-99. PubMed ID: 26778701
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.